TLR7 and melanoma: Additionally,CMC mimics of cancer cell (B16-OVA) membrane and PLGA nanoparticleswere formulated as nanovaccines to specifically targeted antigen-presentingcells (APCs) and enhance their uptake to trigger cell maturation.Imiquimod R837, an adjuvant and agonist for toll-like receptor 7 (TLR-7),was preloaded into PLGA particles and coated with a mannose-modifiedcell membrane.343 These mimics effectivelyinhibited the growth of melanoma tumors when combined with antiprogrammedcell death protein 1 (PD-1) checkpoint blockade therapy.